Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 17439508)

1.

Association between Thiopurine S-methyltransferase Polymorphisms and Thiopurine-Induced Adverse Drug Reactions in Patients with Inflammatory Bowel Disease: A Meta-Analysis.

Liu YP, Wu HY, Yang X, Xu HQ, Li YC, Shi DC, Huang JF, Huang Q, Fu WL.

PLoS One. 2015 Mar 23;10(3):e0121745. doi: 10.1371/journal.pone.0121745. eCollection 2015.

2.

Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease.

Kim MJ, Lee SY, Choe YH.

Yonsei Med J. 2014 Sep;55(5):1289-96. doi: 10.3349/ymj.2014.55.5.1289.

3.

Therapeutic drug monitoring in patients with inflammatory bowel disease.

Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA.

World J Gastroenterol. 2014 Apr 7;20(13):3475-84. doi: 10.3748/wjg.v20.i13.3475. Review.

4.

Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.

Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M.

Saudi J Gastroenterol. 2014 Mar-Apr;20(2):81-101. doi: 10.4103/1319-3767.129473. Review.

5.

Adverse events associated with azathioprine treatment in korean pediatric inflammatory bowel disease patients.

Chun JY, Kang B, Lee YM, Lee SY, Kim MJ, Choe YH.

Pediatr Gastroenterol Hepatol Nutr. 2013 Sep;16(3):171-7. doi: 10.5223/pghn.2013.16.3.171. Epub 2013 Sep 30.

6.

Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.

Osaki R, Imaeda H, Ban H, Aomatsu T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.

Exp Ther Med. 2011 Sep;2(5):783-786. Epub 2011 Jun 16.

7.

Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.

Bradford K, Shih DQ.

World J Gastroenterol. 2011 Oct 7;17(37):4166-73. doi: 10.3748/wjg.v17.i37.4166. Review.

8.

Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis.

Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.

ISRN Gastroenterol. 2011;2011:194324. doi: 10.5402/2011/194324. Epub 2011 May 25.

9.

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk.

Nguyen CM, Mendes MA, Ma JD.

PLoS Curr. 2011 May 15;3:RRN1236. doi: 10.1371/currents.RRN1236.

10.

Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure?

Deshpande AR, Abreu MT.

Therap Adv Gastroenterol. 2010 Sep;3(5):275-9. doi: 10.1177/1756283X10376121. No abstract available.

11.

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.

Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH.

World J Gastroenterol. 2010 Jul 7;16(25):3187-95. Review.

12.

Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.

Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J.

World J Gastroenterol. 2008 Jul 21;14(27):4342-6.

13.

Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics.

Rutherford K, Daggett V.

J Mol Biol. 2008 Jun 13;379(4):803-14. doi: 10.1016/j.jmb.2008.04.032. Epub 2008 Apr 18.

14.

Start low, go slow, but don't go this way yet.

Bressler B, Enns R.

Can J Gastroenterol. 2008 Feb;22(2):121-3. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk